Metformin and Tesamorelin Interaction: Compatible | Peptide Database

FDA-approved for promoting weight regain following involuntary weight loss due to major surgery. Oxandrolone accelerates lean mass recovery and improves nitrogen balance during the recovery period. Extensively studied in severe burn patients, where oxandrolone reduces protein catabolism, accelerates wound healing, shortens hospital stays, and improves long-term lean body mass outcomes. Widely used in major burn centers. Effective for reversing muscle wasting and weight loss in patients with HIV/AIDS. Increases lean body mass and improves functional capacity in wasting syndrome. FDA-approved indication for weight recovery after chronic infections that result in significant involuntary weight loss. Counteracts catabolic effects of prolonged corticosteroid therapy by enhancing nitrogen retention and protein synthesis, helping preserve lean mass during necessary glucocorticoid treatment. FDA-approved for relief of bone pain accompanying osteoporosis. Increases bone mineral density and reduces pain scores in osteoporotic patients, particularly postmenopausal women. Used as adjunctive therapy with growth hormone in girls with Turner syndrome to improve final adult height. Clinical trials show additive benefit when combined with GH therapy. Promotes nitrogen retention and anti-catabolic effects during energy restriction, preserving lean tissue while facilitating fat loss. Commonly used during cutting phases. Increases muscular strength through enhanced protein synthesis and creatine phosphate regeneration, without the water retention associated with aromatizing compounds. Clinical studies have demonstrated selective reduction in abdominal and visceral adipose tissue with oxandrolone treatment, independent of total caloric intake changes.

LGD-4033 is widely regarded as the most potent SARM for lean mass accrual. In the Phase 2 VK5211 trial in hip fracture patients, subjects receiving 1 mg/day gained an average of 1.21 kg of lean body mass over 12 weeks. Higher doses in healthy volunteer studies have shown even greater lean mass increases. Users consistently report LGD-4033 as superior to Ostarine for mass-building purposes. Clinical trial data demonstrated statistically significant improvements in leg press strength in hip fracture patients treated with LGD-4033. Anecdotal reports consistently describe notable strength increases within 3-4 weeks, particularly in compound movements. Strength gains are dose-dependent. The anabolic activity of LGD-4033 without estrogenic water retention makes it suitable for simultaneous lean mass gain and fat reduction. Some water retention can occur due to the compound itself (non-estrogenic mechanism), but overall body composition changes favor a recomposition effect. Clinical data shows favorable shifts in lean-to-fat mass ratio. Viking Therapeutics conducted a Phase 2 trial (VK5211) evaluating LGD-4033 in patients recovering from hip fracture surgery. The trial met its primary endpoint, demonstrating dose-dependent increases in lean body mass at 12 weeks. Secondary endpoints including leg press strength and stair-climbing speed also showed statistically significant improvements versus placebo. Originally developed for conditions involving muscle wasting and age-related muscle loss. Preclinical and early clinical data support the potential to preserve or restore muscle mass in catabolic states. The hip fracture trial results are directly relevant to sarcopenia and frailty in elderly populations. Preclinical data demonstrates that LGD-4033 increases bone mineral density and bone formation markers through direct AR-mediated signaling in osteoblasts. While no dedicated human trial has been completed for this indication, the mechanism supports potential utility in osteoporosis, particularly in populations where traditional androgen therapy is contraindicated.